Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias

New drugs in acute myeloid leukemia: Table 1.

(2016) T. M. Kadia et al.   ANNALS OF ONCOLOGY

FXa variants advance toward a therapy for bleeding

(2015) J. Emsley   BLOOD

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo

(2015) P Arreba-Tutusaus et al.   LEUKEMIA

FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia

(2015) Michael R. Grunwald et al.   SEMINARS IN HEMATOLOGY

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

(2014) L Schafranek et al.   LEUKEMIA

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition

(2013) Pavel Simara et al.   AMERICAN JOURNAL OF HEMATOLOGY

Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis

(2013) T. O'Hare et al.   CANCER RESEARCH

Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells

(2012) M-C Wagner et al.   LEUKEMIA

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells

(2012) Daniel B. Lipka et al.   PLoS One

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

(2008) F. Breitenbuecher et al.   BLOOD

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY